GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats

Physiology and Behavior

Volumn 100, Issue 4, 2010, Pages 291-296

  Rüttimann, Elisabeth B ^a   Arnold, Myrtha ^a   Geary, Nori ^a   Langhans, Wolfgang ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Food intake; Gut peptide; Satiation; Satiety

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; EXENDIN (9-39); GLUCAGON LIKE PEPTIDE 1; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL FOOD; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEEDING BEHAVIOR; FOOD INTAKE; MALE; NONHUMAN; PORTION SIZE; PRIORITY JOURNAL; RAT; SATIETY; TIME; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; EATING; INFUSION; PSYCHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; GLUCAGON-LIKE PEPTIDE 1; INFUSIONS, PARENTERAL; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SATIETY RESPONSE;

EID: 77952956504     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.02.022     Document Type: Article

References (40)

1. Balks H.J., Holst J.J., von zur Mühlen A., Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 1997, 82:786-790.
2. Holst J.J. On the physiology of GIP and GLP-1. Horm Metab Res 2004, 36:747-754.
3. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
4. Iritani N., Sugimoto T., Fukuda H., Komiya M., Ikeda H. Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutr 1999, 129:46-50.
5. Strader A.D., Vahl T.P., Jandacek R.J., Woods S.C., D'Alessio D.A., Seeley R.J. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol 2005, 288:E447-E453.
6. Anini Y., Fu-Cheng X., Cuber J.C., Kervran A., Chariot J., Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflügers Arch 1999, 438:299-306.
7. D'Alessio D., Lu W., Sun W., Zheng S., Yang Q., Seeley R., et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol 2007, 293:R2163-R2169.
8. Jin S.L., Han V.K., Simmons J.G., Towle A.C., Lauder J.M., Lund P.K. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988, 271:519-532.
9. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995, 7:2294-2300.
10. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999, 403:261-280.
11. Nakagawa A., Satake H., Nakabayashi H., Nishizawa M., Furuya K., Nakano S., et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004, 110:36-43.
12. Balkan B., Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol 2000, 279:R1449-R1454.
13. Rüttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
14. Gromada J., Holst J.J., Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch 1998, 435:583-594.
15. Cummings D.E., Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007, 117:13-23.
16. Holst J.J., Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005, 48:612-615.
17. Lutz T.A., Geary N. Gastrointestinal factors in appetite and food intake - animal research. Appetite and food intake 2008, 163-186. CRC Press. R.B.S. Harris, R.D. Mattes (Eds.).
18. Chelikani P.K., Haver A.C., Reidelberger R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol 2005, 288:R1695-R1706.
19. Scott K.A., Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol 2007, 293:R983-R987.
20. Beglinger C., Degen L. Gastrointestinal satiety signals in humans - physiologic roles for GLP-1 and PYY?. Physiol Behav 2006, 89:460-464.
21. Gutzwiller J.P., Drewe J., Göke B., Schmidt H., Rohrer B., Lareida J., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999, 276:R1541-R1544.
22. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
23. Kim D.H., D'Alessio D.A., Woods S.C., Seeley R.J. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul Pept 2009, 155:110-114.
24. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979, 6:65-70.
25. Geary N. Endocrine controls of eating: CCK, leptin, and ghrelin. Physiol Behav 2004, 81:719-733.
26. Smith G.P. Cholecystokinin. a molecular negative-feedback control of eating. Hormones, brain and behavior 2009, 2527-2540. Academic Press, San Diego. D.W. Pfaff, A.P. Arnold, A.M. Etgen, S.E. Farhrbach, R.T. Rubin (Eds.).
27. Naslund E., King N., Mansten S., Adner N., Holst J.J., Gutniak M., et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004, 91:439-446.
28. McHugh P.R., Moran T.H., Barton G.N. Satiety: a graded behavioral phenomenon regulating caloric intake. Science 1975, 190:167-169.
29. Larsen P.J., Fledelius C., Knudsen L.B., Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50:2530-2539.
30. Orskov C., Poulsen S.S., Moller M., Holst J.J. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-1. Diabetes 1996, 45:832-835.
31. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005, 1044:127-131.
32. Talsania T., Anini Y., Siu S., Drucker D.J., Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
33. Lo C.M., Xu M., Yang Q., Zheng S., Carey K.M., Tubb M.R., et al. Effect of intraperitoneal and intravenous administration of cholecystokinin-8 and apolipoprotein AIV on intestinal lymphatic CCK-8 and apo A-IV concentration. Am J Physiol 2009, 296:R43-R50.
34. Cox J.E. Cholecystokinin satiety involves CCKA receptors perfused by the superior pancreaticoduodenal artery. Am J Physiol 1998, 274:R1390-R1396.
35. Weatherford S.C., Chiruzzo F.Y., Laughton W.B. Satiety induced by endogenous and exogenous cholecystokinin is mediated by CCK-A receptors in mice. Am J Physiol 1992, 262:R574-R578.
36. Weatherford S.C., Laughton W.B., Salabarria J., Danho W., Tilley J.W., Netterville L.A., et al. CCK satiety is differentially mediated by high-and low-affinity CCK receptors in mice and rats. Am J Physiol 1993, 264:R244-R249.
37. Qin X., Shen H., Liu M., Yang Q., Zheng S., Sabo M., et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol 2005, 288:G943-G949.
38. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55:3387-3393.
39. Schneider L.H., Murphy R.B., Gibbs J., Smith G.P. Comparative potencies of CCK antagonists for the reversal of the satiating effect of cholecystokinin. Cholecystokinin antagonists 1988, 263-284. Liss, New York. R.W. Wang, R. Shoenfeldt (Eds.).
40. Scrocchi L.A., Brown T.J., MacLusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996, 2:1254-1258.